- Home
- BBDO vs BIIB Comparison
BBDO vs BIIB Comparison
Compare BBDO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBDO
- BIIB
- Stock Information
- Founded
- BBDO 1943
- BIIB 1978
- Country
- BBDO Brazil
- BIIB United States
- Employees
- BBDO N/A
- BIIB N/A
- Industry
- BBDO Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- BBDO Finance
- BIIB Health Care
- Exchange
- BBDO Nasdaq
- BIIB Nasdaq
- Market Cap
- BBDO 28.5B
- BIIB 18.7B
- IPO Year
- BBDO N/A
- BIIB 1991
- Fundamental
- Price
- BBDO $2.79
- BIIB $143.32
- Analyst Decision
- BBDO Strong Buy
- BIIB Buy
- Analyst Count
- BBDO 4
- BIIB 27
- Target Price
- BBDO $2.55
- BIIB $188.09
- AVG Volume (30 Days)
- BBDO 29.5K
- BIIB 1.5M
- Earning Date
- BBDO 10-30-2025
- BIIB 10-29-2025
- Dividend Yield
- BBDO 4.15%
- BIIB N/A
- EPS Growth
- BBDO 58.81
- BIIB 31.67
- EPS
- BBDO 0.36
- BIIB 10.45
- Revenue
- BBDO $16,114,445,927.00
- BIIB $9,997,000,000.00
- Revenue This Year
- BBDO $72.65
- BIIB $2.00
- Revenue Next Year
- BBDO $8.90
- BIIB N/A
- P/E Ratio
- BBDO $8.13
- BIIB $13.78
- Revenue Growth
- BBDO 27.09
- BIIB 3.36
- 52 Week Low
- BBDO $1.71
- BIIB $110.04
- 52 Week High
- BBDO $2.88
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- BBDO 63.77
- BIIB 57.98
- Support Level
- BBDO $2.69
- BIIB $139.54
- Resistance Level
- BBDO $2.80
- BIIB $150.28
- Average True Range (ATR)
- BBDO 0.07
- BIIB 4.43
- MACD
- BBDO 0.01
- BIIB 0.47
- Stochastic Oscillator
- BBDO 89.28
- BIIB 62.90
About BBDO Banco Bradesco Sa (each representing one Common Share)
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.